127 related articles for article (PubMed ID: 34668877)
1. Can Quetiapine Prolong the Antidepressant Effect of Ketamine?: A 5-Year Follow-up Study.
Amiaz R; Saporta R; Noy A; Berkenstadt H; Weiser M
J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):673-675. PubMed ID: 34668877
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
[TBL] [Abstract][Full Text] [Related]
3. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Reif A; Bitter I; Buyze J; Cebulla K; Frey R; Fu DJ; Ito T; Kambarov Y; Llorca PM; Oliveira-Maia AJ; Messer T; Mulhern-Haughey S; Rive B; von Holt C; Young AH; Godinov Y;
N Engl J Med; 2023 Oct; 389(14):1298-1309. PubMed ID: 37792613
[TBL] [Abstract][Full Text] [Related]
4. Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study).
Marwood L; Taylor R; Goldsmith K; Romeo R; Holland R; Pickles A; Hutchinson J; Dietch D; Cipriani A; Nair R; Attenburrow MJ; Young AH; Geddes J; McAllister-Williams RH; Cleare AJ
BMC Psychiatry; 2017 Jun; 17(1):231. PubMed ID: 28651526
[TBL] [Abstract][Full Text] [Related]
5. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
Bauer M; Dell'osso L; Kasper S; Pitchot W; Dencker Vansvik E; Köhler J; Jørgensen L; Montgomery SA
J Affect Disord; 2013 Oct; 151(1):209-19. PubMed ID: 23810357
[TBL] [Abstract][Full Text] [Related]
6. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
[TBL] [Abstract][Full Text] [Related]
7. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
Saad Z; Hibar D; Fedgchin M; Popova V; Furey ML; Singh JB; Kolb H; Drevets WC; Chen G
Int J Neuropsychopharmacol; 2020 Dec; 23(9):549-558. PubMed ID: 32367114
[TBL] [Abstract][Full Text] [Related]
8. Association between depression subtypes and response to repeated-dose intravenous ketamine.
Wang C; Zhou Y; Zheng W; Liu W; Zhan Y; Li H; Chen L; Zhang B; Walter M; Li M; Li MD; Ning Y
Acta Psychiatr Scand; 2019 Nov; 140(5):446-457. PubMed ID: 31483855
[TBL] [Abstract][Full Text] [Related]
9. Intravenous arketamine for treatment-resistant depression: open-label pilot study.
Leal GC; Bandeira ID; Correia-Melo FS; Telles M; Mello RP; Vieira F; Lima CS; Jesus-Nunes AP; Guerreiro-Costa LNF; Marback RF; Caliman-Fontes AT; Marques BLS; Bezerra MLO; Dias-Neto AL; Silva SS; Sampaio AS; Sanacora G; Turecki G; Loo C; Lacerda ALT; Quarantini LC
Eur Arch Psychiatry Clin Neurosci; 2021 Apr; 271(3):577-582. PubMed ID: 32078034
[TBL] [Abstract][Full Text] [Related]
10. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression.
Rivas-Grajales AM; Salas R; Robinson ME; Qi K; Murrough JW; Mathew SJ
Int J Neuropsychopharmacol; 2021 May; 24(5):383-391. PubMed ID: 33249434
[TBL] [Abstract][Full Text] [Related]
11. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.
Cornwell BR; Salvadore G; Furey M; Marquardt CA; Brutsche NE; Grillon C; Zarate CA
Biol Psychiatry; 2012 Oct; 72(7):555-61. PubMed ID: 22521148
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
[TBL] [Abstract][Full Text] [Related]
13. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
[TBL] [Abstract][Full Text] [Related]
14. Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression.
Kanba S; Murasaki M; Koyama T; Takeuchi M; Shimizu Y; Arita E; Kuroishi K; Takeuchi M; Kamei S
BMC Psychiatry; 2019 Jun; 19(1):198. PubMed ID: 31242884
[TBL] [Abstract][Full Text] [Related]
15. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
Shiroma PR; Johns B; Kuskowski M; Wels J; Thuras P; Albott CS; Lim KO
J Affect Disord; 2014 Feb; 155():123-9. PubMed ID: 24268616
[TBL] [Abstract][Full Text] [Related]
16. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.
Wilkinson ST; Wright D; Fasula MK; Fenton L; Griepp M; Ostroff RB; Sanacora G
Psychother Psychosom; 2017; 86(3):162-167. PubMed ID: 28490030
[TBL] [Abstract][Full Text] [Related]
17. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
Singh JB; Fedgchin M; Daly EJ; Drevets WC
Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
[TBL] [Abstract][Full Text] [Related]
18. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M
Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373
[TBL] [Abstract][Full Text] [Related]
19. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
[TBL] [Abstract][Full Text] [Related]
20. Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy.
Allen AP; Naughton M; Dowling J; Walsh A; O'Shea R; Shorten G; Scott L; McLoughlin DM; Cryan JF; Clarke G; Dinan TG
J Psychiatr Res; 2018 May; 100():24-32. PubMed ID: 29475018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
